CPRIT held a webinar on November 19th to help potential applicants navigating the grant opportunities available through CPRIT’s Product Development Research Program, providing an overview of the TXCO, RELCO and SEED grant applications, including review criteria, the application process, and tips for success.
Resources from the webinar, including a session recording, frequently asked questions (FAQ) and slides, can be viewed on the CPRIT website.
On November 9th, CPRIT released three requests for applications:
Texas Company Product Development Research Awards (TXCO)
This award mechanism seeks to support early-stage "startup" and established companies in the development of innovative products, services, and infrastructure with significant potential impact on cancer patient care.
The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust cancer biotech industry; or must fill a treatment or research gap. Companies must be headquartered in Texas.
Company Relocation Product Development Research Awards (RELCO)
This award mechanism seeks to support early-stage "startup" and established companies in the development of innovative products, services, and infrastructure with significant potential impact on cancer patient care.
The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust cancer biotech industry; or must fill a treatment or research gap. Companies must relocate to Texas upon receipt of award.
Seed Awards for Product Development Research (SEED)
This award mechanism seeks to support early-stage "startup" companies in the development of innovative products, services, and infrastructure with significant potential impact on cancer patient care.
The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust cancer biotech industry; or must fill a treatment or research gap. Company applicants must be headquartered in Texas or be willing to relocate to Texas upon receipt of award.
The application submission portal opened December 2, 2020 and closes January 27, 2021.